Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder

Go back to Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
(NASDAQ: DFTX) Delayed: 39.28 +0.47 (1.21%)
Previous Close $38.81    52 Week High
Open $39.00    52 Week Low
Day High $39.54    P/E N/A 
Day Low $37.97    EPS
Volume 2,037,992